MA50533A - Imipridones pour gliomes - Google Patents

Imipridones pour gliomes

Info

Publication number
MA50533A
MA50533A MA050533A MA50533A MA50533A MA 50533 A MA50533 A MA 50533A MA 050533 A MA050533 A MA 050533A MA 50533 A MA50533 A MA 50533A MA 50533 A MA50533 A MA 50533A
Authority
MA
Morocco
Prior art keywords
imipridones
gliomas
Prior art date
Application number
MA050533A
Other languages
English (en)
Inventor
Joshua E Allen
Varun Vijay Prabhu
Martin Stogniew
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of MA50533A publication Critical patent/MA50533A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA050533A 2017-11-03 2018-11-05 Imipridones pour gliomes MA50533A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581478P 2017-11-03 2017-11-03
US15/947,840 US10172862B2 (en) 2017-01-30 2018-04-08 Imipridones for gliomas

Publications (1)

Publication Number Publication Date
MA50533A true MA50533A (fr) 2020-09-09

Family

ID=63038820

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050533A MA50533A (fr) 2017-11-03 2018-11-05 Imipridones pour gliomes

Country Status (15)

Country Link
US (5) US10172862B2 (fr)
EP (1) EP3703681A4 (fr)
JP (2) JP7319989B2 (fr)
KR (2) KR20250102119A (fr)
CN (2) CN116173036A (fr)
AU (2) AU2018360752A1 (fr)
BR (1) BR112020008791A2 (fr)
CA (1) CA3080815A1 (fr)
EA (1) EA202090928A1 (fr)
IL (1) IL274194A (fr)
MA (1) MA50533A (fr)
MX (2) MX2020004375A (fr)
NZ (1) NZ764026A (fr)
SG (1) SG11202003952YA (fr)
WO (1) WO2019090222A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66519B1 (sr) 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2020172485A1 (fr) * 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Procédés d'utilisation d'imipridones
EP4192467A1 (fr) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthèse de nouveaux dérivés d'imipridone et leur évaluation concernant leur activité anticancéreuse
CN114957236B (zh) * 2021-02-25 2026-02-03 南京正大天晴制药有限公司 一种2-酰基氨基噻唑类化合物的制备方法
CN113248465B (zh) * 2021-06-16 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种鹰嘴豆芽素a的合成方法
CN114632088B (zh) * 2022-05-16 2022-08-16 北京市神经外科研究所 阿糖胞苷化合物在制备治疗脊髓胶质瘤的药物中的用途
KR20250056926A (ko) * 2022-08-05 2025-04-28 키메릭스 인크. 신경교종 치료를 위한 약학적 조성물 및 이의 용도
CN117731654B (zh) * 2024-02-18 2024-05-07 首都医科大学附属北京天坛医院 Jjh201601在初发性脑胶质瘤和复发性脑胶质瘤治疗中的新用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1638178A (en) * 1924-11-04 1927-08-09 Union Switch & Signal Co Railway-traffic-controlling apparatus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
WO2004082570A2 (fr) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US8463365B2 (en) * 2007-09-19 2013-06-11 Oncofluor, Inc. Method for imaging and treating organs and tissues
CA2841142C (fr) * 2010-06-23 2020-12-15 Ryan D. Morin Biomarqueurs pour lymphomes non hodgkiniens et leurs utilisations
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
PT2701708T (pt) 2011-04-29 2020-05-08 Penn State Res Found Indução de gene trail de moléculas pequenas através de células tumorais e normais como uma terapia anticancro
US9688679B2 (en) * 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
HUE044238T2 (hu) * 2013-03-13 2019-10-28 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra
WO2015073072A1 (fr) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR20250006309A (ko) * 2013-11-15 2025-01-10 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온,이의 염 및 이의 용도
SMT202400497T1 (it) 2014-03-31 2025-01-14 Scripps Research Inst Farmacoforo per induzione di trail
CN113149985B (zh) * 2015-01-30 2025-01-28 昂克希尔迪克斯有限公司 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) * 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
MX2023013341A (es) 2023-11-27
US10172862B2 (en) 2019-01-08
US20240366613A1 (en) 2024-11-07
KR20200117979A (ko) 2020-10-14
WO2019090222A1 (fr) 2019-05-09
US20180221375A1 (en) 2018-08-09
JP2023139152A (ja) 2023-10-03
KR20250102119A (ko) 2025-07-04
US10369154B2 (en) 2019-08-06
US12102639B2 (en) 2024-10-01
US20210236499A1 (en) 2021-08-05
CA3080815A1 (fr) 2019-05-09
AU2024219839A1 (en) 2024-10-10
JP7319989B2 (ja) 2023-08-02
EP3703681A1 (fr) 2020-09-09
CN111818919A (zh) 2020-10-23
MX2020004375A (es) 2020-11-11
JP2021502417A (ja) 2021-01-28
BR112020008791A2 (pt) 2020-10-20
IL274194A (en) 2020-06-30
US20190183895A1 (en) 2019-06-20
EA202090928A1 (ru) 2020-08-14
US10946022B2 (en) 2021-03-16
KR102826312B1 (ko) 2025-06-26
EP3703681A4 (fr) 2021-08-11
US20200022982A1 (en) 2020-01-23
AU2018360752A1 (en) 2020-05-21
CN116173036A (zh) 2023-05-30
SG11202003952YA (en) 2020-05-28
NZ764026A (en) 2025-12-19

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3347458A4 (fr) Cochon multi-transgénique pour xénogreffe
EP3359194A4 (fr) Conjugué anticorps-médicament pour applications anti-inflammatoires
EP3630078A4 (fr) Agents pour chimio-embolisation
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
MA50533A (fr) Imipridones pour gliomes
FR3036518B1 (fr) Inversion pour contrainte tectonique
DK3351526T3 (da) Diisopentylterephthalat
IL261341B (en) Branch instruction
DK3568655T3 (da) Rekuperator
DK3387930T3 (da) Stofanordning
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da) Genterapi
IT201700108243A1 (it) Confezione
EP3728590C0 (fr) Nouvelles thiophosphoramidites
DK3576686T3 (da) Brokbind
DK3568506T3 (da) Offeranode
EP3521145A4 (fr) Structure pour véhicule
EP3388149A4 (fr) Structure de pilier pour biopuce
DK3510051T3 (da) Carboxylalkylchitosan
DK3714101T3 (da) Sporskifte
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse
DK3576718T3 (da) Pastil